Q/C Technologies (QCLS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
6 Mar, 2026Executive summary
Annual meeting scheduled for May 20, 2025, to be held virtually, with voting on key proposals affecting governance and capital structure.
Board recommends voting in favor of all proposals, including director elections, auditor ratification, reverse stock split, share increase, preferred stock amendment, and adjournment.
Record date for voting is March 25, 2025; multiple classes of stock with varying voting rights are eligible to vote.
Voting matters and shareholder proposals
Six directors to be elected for one-year terms.
Ratification of Stephano Slack LLC as independent auditor for 2025.
Proposal to effect a reverse stock split at a ratio between 1-for-2 and 1-for-100, at Board discretion, to maintain Nasdaq listing.
Proposal to increase authorized common shares from 250M to 1.25B and total capital stock to 1.3B.
Proposal to authorize Board to increase stated value of Series F and F-1 Preferred Stock up to $1,250 per share.
Proposal to adjourn the meeting if more time is needed to solicit votes.
Board of directors and corporate governance
Board will be reduced from seven to six members after the meeting.
All current nominees have significant industry, financial, or governance experience.
Board committees include Audit, Compensation, Nominating and Corporate Governance, and Risk and Disclosure.
Majority of directors are independent under Nasdaq rules.
No formal board diversity policy, but diversity of experience and skills considered.
Latest events from Q/C Technologies
- Registering 6.5M shares for resale, with major dilution and capital needs amid business diversification.QCLS
Registration Filing6 Mar 2026 - Net loss increased to $27.2 million in 2024, with urgent need for new funding to sustain operations.QCLS
Q4 20246 Mar 2026 - Shareholders will vote on key proposals to enable major financings and expand authorized shares.QCLS
Proxy Filing6 Mar 2026 - Net loss narrowed, but going concern and Nasdaq compliance risks persist amid ongoing clinical development.QCLS
Q2 20256 Mar 2026 - Net loss reached $24M YTD; cash and securities at $10.6M; liquidity sufficient for 12 months.QCLS
Q3 20246 Mar 2026 - Stockholders will vote on directors, equity plan expansion, auditor ratification, and adjournment.QCLS
Proxy Filing6 Mar 2026 - Transitioned to laser-based computing for blockchain, raising $9.4M and narrowing net loss.QCLS
Q3 20256 Mar 2026 - Net loss widened to $21.3M as new financings and warrant amendments strengthened liquidity.QCLS
Q2 20246 Mar 2026 - Shareholders to vote on major share issuances, incentive plan expansion, and a reverse stock split.QCLS
Proxy Filing6 Mar 2026